Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$2.50
-8.3%
$2.48
$1.78
$10.14
$51.91M0.7264,115 shs49,906 shs
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
$9.45
-0.7%
$8.69
$6.60
$14.60
$2.24B1.366,869 shs2,706 shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$147.91
-1.2%
$136.18
$122.80
$219.34
$4.27B0.67287,559 shs172,893 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$11.15
+1.1%
$11.22
$5.78
$22.00
$1.42B2.39276,970 shs192,768 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$38.10
-1.0%
$33.38
$27.12
$60.90
$2.27B2.41968,956 shs435,828 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
+7.09%+14.05%-2.51%-20.70%-65.04%
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
+4.39%+7.69%-0.10%+27.27%+5.31%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+0.56%+4.71%+8.34%-9.25%-22.58%
Mesoblast Limited stock logo
MESO
Mesoblast
+4.85%+2.13%-13.30%+8.68%+48.32%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-1.66%+0.94%+11.67%-0.98%-24.55%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
4.0813 of 5 stars
3.43.00.04.80.02.50.6
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/AN/AN/AN/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
4.5826 of 5 stars
3.51.00.04.72.92.51.9
Mesoblast Limited stock logo
MESO
Mesoblast
1.8217 of 5 stars
3.51.00.00.01.80.80.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.9863 of 5 stars
3.42.00.04.42.60.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
2.80
Moderate Buy$23.80853.91% Upside
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
0.00
N/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
3.00
Buy$213.7544.51% Upside
Mesoblast Limited stock logo
MESO
Mesoblast
3.00
Buy$18.0061.51% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4032.30% Upside

Current Analyst Ratings Breakdown

Latest ADVM, TWST, KRYS, MESO, and BVNRY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$155.00 ➝ $176.00
6/26/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$16.00 ➝ $12.00
6/24/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$240.00
5/16/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.00
5/15/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.00
5/15/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
5/15/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/7/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$195.00 ➝ $189.00
5/7/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$219.00 ➝ $219.00
5/6/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$240.00 ➝ $240.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$1M52.12N/AN/A$3.40 per share0.73
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
$829.12M2.70$1.05 per share9.01$6.99 per share1.35
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$290.52M14.71$4.61 per share32.11$32.90 per share4.50
Mesoblast Limited stock logo
MESO
Mesoblast
$5.90M241.37N/AN/A$4.21 per share2.65
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M7.29N/AN/A$8.07 per share4.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$130.93M-$6.40N/AN/AN/AN/A-130.53%-66.31%8/11/2025 (Estimated)
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
$143.26M$0.8011.819.00N/A21.11%11.89%9.32%8/28/2025 (Estimated)
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$89.16M$4.1635.5314.67N/A37.17%14.64%13.28%8/4/2025 (Estimated)
Mesoblast Limited stock logo
MESO
Mesoblast
-$87.96MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/1/2025 (Estimated)

Latest ADVM, TWST, KRYS, MESO, and BVNRY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.20N/AN/AN/A$95.42 millionN/A
8/1/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54N/AN/AN/A$95.52 millionN/A
5/9/2025Q1 2025
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/A$0.13N/A$0.13N/A$189.89 million
5/6/2025Q1 2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.38$1.20-$0.18$1.20$98.66 million$88.18 million
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
4/15/2025Q4 2024
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$1.34-$1.96-$0.62-$1.96N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/AN/AN/AN/AN/A
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/A
3.57
3.57
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/A
2.81
1.44
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
9.65
9.27
Mesoblast Limited stock logo
MESO
Mesoblast
0.22
0.96
0.63
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24

Institutional Ownership

CompanyInstitutional Ownership
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
48.17%
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
Mesoblast Limited stock logo
MESO
Mesoblast
1.43%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
6.00%
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
13.70%
Mesoblast Limited stock logo
MESO
Mesoblast
18.80%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
19020.89 million19.64 millionOptionable
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
1,611236.57 millionN/ANot Optionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
21028.90 million24.94 millionOptionable
Mesoblast Limited stock logo
MESO
Mesoblast
80127.78 million103.76 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adverum Biotechnologies stock logo

Adverum Biotechnologies NASDAQ:ADVM

$2.50 -0.23 (-8.27%)
As of 03:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Bavarian Nordic stock logo

Bavarian Nordic OTCMKTS:BVNRY

$9.45 -0.07 (-0.74%)
As of 09:30 AM Eastern

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$147.91 -1.83 (-1.22%)
As of 03:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Mesoblast stock logo

Mesoblast NASDAQ:MESO

$11.14 +0.13 (+1.13%)
As of 03:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$38.10 -0.38 (-0.97%)
As of 03:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.